

Lynley V Marshall

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5524085/publications.pdf>

Version: 2024-02-01

44
papers

1,868
citations

471509
17
h-index

315739
38
g-index

45
all docs

45
docs citations

45
times ranked

3064
citing authors

#	ARTICLE	IF	CITATIONS
1	Integrated Molecular Meta-Analysis of 1,000 Pediatric High-Grade and Diffuse Intrinsic Pontine Glioma. <i>Cancer Cell</i> , 2017, 32, 520-537.e5.	16.8	716
2	Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1â€“2 trial. <i>Lancet Oncology</i> , The, 2020, 21, 121-133.	10.7	204
3	Infant High-Grade Gliomas Comprise Multiple Subgroups Characterized by Novel Targetable Gene Fusions and Favorable Outcomes. <i>Cancer Discovery</i> , 2020, 10, 942-963.	9.4	157
4	Functional diversity and cooperativity between subclonal populations of pediatric glioblastoma and diffuse intrinsic pontine glioma cells. <i>Nature Medicine</i> , 2018, 24, 1204-1215.	30.7	133
5	Atezolizumab for children and young adults with previously treated solid tumours, non-Hodgkin lymphoma, and Hodgkin lymphoma (iMATRIX): a multicentre phase 1â€“2 study. <i>Lancet Oncology</i> , The, 2020, 21, 134-144.	10.7	103
6	ACCELERATE and European Medicines Agency Paediatric Strategy Forum for medicinal product development of checkpoint inhibitors for use in combination therapy in paediatric patients. <i>European Journal of Cancer</i> , 2020, 127, 52-66.	2.8	52
7	A tailored molecular profiling programme for children with cancer to identify clinically actionable genetic alterations. <i>European Journal of Cancer</i> , 2019, 121, 224-235.	2.8	44
8	ACCELERATE and European Medicine Agency Paediatric Strategy Forum for medicinal product development for mature B-cell malignancies in children. <i>European Journal of Cancer</i> , 2019, 110, 74-85.	2.8	39
9	Entrectinib in children and young adults with solid or primary CNS tumors harboring <i>NTRK</i>, <i>ROS1</i>, or <i>ALK</i> aberrations (STARTRK-NC). <i>Neuro-Oncology</i> , 2022, 24, 1776-1789.	1.2	37
10	Second Paediatric Strategy Forum for anaplastic lymphoma kinase (ALK) inhibition in paediatric malignancies. <i>European Journal of Cancer</i> , 2021, 157, 198-213.	2.8	34
11	Accelerating drug development for neuroblastoma - New Drug Development Strategy: an Innovative Therapies for Children with Cancer, European Network for Cancer Research in Children and Adolescents and International Society of Paediatric Oncology Europe Neuroblastoma project. <i>Expert Opinion on Drug Discovery</i> , 2017, 12, 1-11.	5.0	28
12	ACCELERATE â€“ Five years accelerating cancer drug development for children and adolescents. <i>European Journal of Cancer</i> , 2022, 166, 145-164.	2.8	28
13	Droplet digital PCR-based detection of circulating tumor DNA from pediatric high grade and diffuse midline glioma patients. <i>Neuro-Oncology Advances</i> , 2021, 3, v013.	0.7	27
14	Paediatric Strategy Forum for medicinal product development of chimeric antigen receptor T-cells in children and adolescents with cancer. <i>European Journal of Cancer</i> , 2022, 160, 112-133.	2.8	24
15	10-year report on the European Paediatric Regulation and its impact on new drugs for children's cancers. <i>Lancet Oncology</i> , The, 2018, 19, 285-287.	10.7	20
16	Paediatric Strategy Forum for medicinal product development of epigenetic modifiers for children. <i>European Journal of Cancer</i> , 2020, 139, 135-148.	2.8	20
17	First-in-child phase I/II study of the dual mTORC1/2 inhibitor vistusertib (AZD2014) as monotherapy and in combination with topotecan-temozolomide in children with advanced malignancies: arms E and F of the AcSÂ©-ESMART trial. <i>European Journal of Cancer</i> , 2021, 157, 268-277.	2.8	19
18	Development of a targeted sequencing approach to identify prognostic, predictive and diagnostic markers in paediatric solid tumours. <i>Oncotarget</i> , 2017, 8, 112036-112050.	1.8	16

#	ARTICLE	IF	CITATIONS
19	Impact of COVID-19 in paediatric early-phase cancer clinical trials in Europe: A report from the Innovative Therapies for Children with Cancer (ITCC) consortium. European Journal of Cancer, 2020, 141, 82-91.	2.8	15
20	DIPG Harbors Alterations Targetable by MEK Inhibitors, with Acquired Resistance Mechanisms Overcome by Combinatorial Inhibition. Cancer Discovery, 2022, 12, 712-729.	9.4	15
21	Circulating tumour DNA sequencing to determine therapeutic response and identify tumour heterogeneity in patients with paediatric solid tumours. European Journal of Cancer, 2022, 162, 209-220.	2.8	12
22	Phase 1/2 KEYNOTE-051 study of pembrolizumab (pembro) in pediatric patients (pts) with advanced melanoma or a PD-L1⁺ advanced, relapsed, or refractory solid tumor or lymphoma.. Journal of Clinical Oncology, 2017, 35, 10525-10525.	1.6	11
23	Final analysis of phase I study of ceritinib in pediatric patients with malignancies harboring activated anaplastic lymphoma kinase (ALK).. Journal of Clinical Oncology, 2020, 38, 10505-10505.	1.6	11
24	KEYNOTE-051: An update on the phase 2 results of pembrolizumab (pembro) in pediatric patients (pts) with advanced melanoma or a PD-L1&sup>+</sup> positive advanced, relapsed or refractory solid tumor or lymphoma.. Journal of Clinical Oncology, 2018, 36, 10525-10525.	1.6	10
25	Treatment outcome with a selective RET tyrosine kinase inhibitor selpercatinib in children with multiple endocrine neoplasia type 2 and advanced medullary thyroid carcinoma. European Journal of Cancer, 2021, 158, 38-46.	2.8	9
26	Paediatric Strategy Forum for medicinal product development of multi-targeted kinase inhibitors in bone sarcomas. European Journal of Cancer, 2022, 173, 71-90.	2.8	9
27	Post-radiotherapy apparent diffusion coefficient (ADC) in children and young adults with high-grade gliomas and diffuse intrinsic pontine gliomas. Pediatric Hematology and Oncology, 2019, 36, 103-112.	0.8	7
28	Phase 2 Study of Pomalidomide (CC-4047) Monotherapy for Children and Young Adults With Recurrent or Progressive Primary Brain Tumors. Frontiers in Oncology, 2021, 11, 660892.	2.8	7
29	High grade gliomas in young children: The South Thames Neuro-Oncology unit experience and recent advances in molecular biology and targeted therapies. Pediatric Hematology and Oncology, 2021, 38, 707-721.	0.8	6
30	Phase I study of regorafenib in combination with vincristine and irinotecan in pediatric patients with recurrent or refractory solid tumors.. Journal of Clinical Oncology, 2020, 38, 10507-10507.	1.6	6
31	PDTM-33. ATRX LOSS CONFERS ENHANCED SENSITIVITY TO COMBINED PARP INHIBITION AND RADIOTHERAPY IN PAEDIATRIC GLIOBLASTOMA MODELS. Neuro-Oncology, 2018, 20, vi210-vi211.	1.2	5
32	High-dose etoposide and cyclophosphamide in adults and children with primary refractory and multiply relapsed acute leukaemias: The Royal Marsden experience. Leukemia Research, 2019, 85, 106217.	0.8	5
33	Revisiting the definition of dose-limiting toxicities in paediatric oncology phase I clinical trials: An analysis from the Innovative Therapies for Children with Cancer Consortium. European Journal of Cancer, 2017, 86, 275-284.	2.8	4
34	A phase II clinical study of pomalidomide (CC-4047) monotherapy for children and young adults with recurrent or progressive primary brain tumors.. Journal of Clinical Oncology, 2019, 37, 10035-10035.	1.6	4
35	MODL-20. A BIOBANK OF ~100 PATIENT-DERIVED MODELS REPRESENTING BIOLOGICAL HETEROGENEITY AND DISTINCT THERAPEUTIC DEPENDENCIES IN PAEDIATRIC HIGH GRADE GLIOMA AND DIPG. Neuro-Oncology, 2020, 22, iii414-iii415.	1.2	2
36	HGG-23. DRUG SCREENING LINKED TO MOLECULAR PROFILING IDENTIFIES NOVEL DEPENDENCIES IN PATIENT-DERIVED PRIMARY CULTURES OF PAEDIATRIC HIGH GRADE GLIOMA AND DIPG. Neuro-Oncology, 2018, 20, i93-i94.	1.2	1

#	ARTICLE	IF	CITATIONS
37	How to address challenges and opportunities in pediatric cancer drug development?. Expert Opinion on Drug Discovery, 2020, 15, 869-872.	5.0	1
38	HG-99A PATIENT-DERIVED PAEDIATRIC HIGH GRADE GLIOMA AND DIPG CELL CULTURE PANEL RECAPITULATING THE GENOTYPIC AND PHENOTYPIC DIVERSITY OF THE DISEASE. Neuro-Oncology, 2016, 18, iii71.3-iii71.	1.2	0
39	PDTM-34. TARGETING H3.3G34R/V RE-WIRING OF THE EPIGENOME IN PAEDIATRIC GLIOBLASTOMA OF CHILDREN AND YOUNG ADULTS. Neuro-Oncology, 2018, 20, vi211-vi211.	1.2	0
40	EAPH-05. MOLECULAR PROFILING AND IDENTIFICATION OF TARGETED THERAPIES FOR CHILDREN AND YOUNG ADULTS WITH PRIMARY CENTRAL NERVOUS SYSTEM TUMOURS IN THE UNITED KINGDOM. Neuro-Oncology, 2018, 20, i66-i66.	1.2	0
41	PDTM-31. DRUG SCREENING LINKED TO MOLECULAR PROFILING IDENTIFIES NOVEL DEPENDENCIES IN PATIENT-DERIVED PRIMARY CULTURES OF PAEDIATRIC HIGH GRADE GLIOMA AND DIPG. Neuro-Oncology, 2018, 20, vi210-vi210.	1.2	0
42	HGG-13. SURVIVAL OUTCOMES OF CHILDREN AND ADOLESCENTS WITH BI-THALAMIC GLIOMAS: THE SOUTH THAMES NEURO-ONCOLOGY UNIT EXPERIENCE. Neuro-Oncology, 2018, 20, i91-i91.	1.2	0
43	Phase 1/2 study of pembrolizumab (pembro) in children with advanced melanoma or a PD-L1-positive (PD-L1 ⁺) advanced, relapsed, or refractory solid tumor or lymphoma (KEYNOTE-051).. Journal of Clinical Oncology, 2016, 34, TPS10585-TPS10585.	1.6	0
44	Phase I trial of lorlatinib in combination with topotecan/cyclophosphamide in children with ALK-driven refractory or relapsed neuroblastoma: A new approaches to neuroblastoma therapy consortium study.. Journal of Clinical Oncology, 2022, 40, 10041-10041.	1.6	0